Adjuvant Therapy With Capecitabine Postpones Recurrence of Hepatocellular Carcinoma After Curative Resection: A Randomized Controlled Trial (original) (raw)

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
  Article PubMed Google Scholar
• Yu SZ. Primary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol. 1995;10:674–82.
  Article CAS PubMed Google Scholar
• Chang CH, Chau GY, Lui WY, Tsay SH, King KL, Wu CW. Long-term results of hepatic resection for hepatocellular carcinoma originating from the noncirrhotic liver. Arch Surg. 2004;139:320–5; discussion 326.
  Article PubMed Google Scholar
• Tung-Ping PR, Fan ST, Wong J. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10–24.
  Article Google Scholar
• Lai EC, Lo CM, Fan ST, Liu CL, Wong J. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: a randomized controlled trial. Arch Surg. 1998;133:183–8.
  Article CAS PubMed Google Scholar
• Takenaka K, Yoshida K, Nishizaki T, Korenaga D, Hiroshige K, Ikeda T, Sugimachi K. Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg. 1995;169:400–4; discussion 405.
  Article CAS PubMed Google Scholar
• Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245:831–42.
  Article PubMed Google Scholar
• Takayama T, Sekine T, Makuuchi M, et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000;356:802–7.
  Article CAS PubMed Google Scholar
• Muto Y, Moriwaki H, Ninomiya M, et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996;334:1561–7.
  Article CAS PubMed Google Scholar
• Ono T, Yamanoi A, Nazmy EAO, Kohno H, Nagasue N. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer. 2001;91:2378–85.
  Article CAS PubMed Google Scholar
• Yamamoto M, Arii S, Sugahara K, Tobe T. Adjuvant oral chemotherapy to prevent recurrence after curative resection for hepatocellular carcinoma. Br J Surg. 1996;83:336–40.
  Article CAS PubMed Google Scholar
• Kohno H, Nagasue N, Hayashi T, et al. Postoperative adjuvant chemotherapy after radical hepatic resection for hepatocellular carcinoma (HCC). Hepatogastroenterology. 1996;43:1405–9.
  CAS PubMed Google Scholar
• Ono T, Nagasue N, Kohno H, Hayashi T, Uchida M, Yukaya H, Yamanoi A, et al. Adjuvant chemotherapy with epirubicin and carmofur after radical resection of hepatocellular carcinoma: a prospective randomized study. Semin Oncol. 1997;24:S6-18–S6-25.
  Google Scholar
• Hasegawa K, Takayama T, Ijichi M, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: a randomized trial. Hepatology. 2006;44:891–5.
  Article CAS PubMed Google Scholar
• Schuller J, Cassidy J, Dumont E, et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–7.
  Article CAS PubMed Google Scholar
• Ishikawa T, Utoh M, Sawada N, Nishida M, Fukase Y, Sekiguchi F, Ishitsuka H. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol. 1998;55:1091–7.
  Article CAS PubMed Google Scholar
• Zhou J, Tang ZY, Fan J, et al. Capecitabine inhibits postoperative recurrence and metastasis after liver cancer resection in nude mice with relation to the expression of platelet-derived endothelial cell growth factor. Clin Cancer Res. 2003;9:6030–7.
  CAS PubMed Google Scholar
• Zhou J, Tang ZY, Wu ZQ, et al. Capecitabine inhibition of recurrence and metastasis after liver cancer resection in nude mice. Chin J Surg. 2001;39:199–201.
  Google Scholar
• Zhou J, Tang ZY, Fan J, et al. Study on inhibition of the growth and metastasis of LCID20 hepatocellular carcinoma by capecitabine. Chin J Exp Surg. 2000;17:403–5.
  Google Scholar
• Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Hepatectomy for hepatocellular carcinoma: toward zero hospital deaths. Ann Surg. 1999;229:322–30.
  Article CAS PubMed Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698–711.
  Article PubMed Google Scholar
• Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet. 1999;353:797–801.
  Article CAS PubMed Google Scholar
• Lau WY, Lai EC, Leung TW, Yu SC. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg. 2008;247:43–8.
  Article PubMed Google Scholar
• Boucher E, Bouguen G, Garin E, Guillygomarch A, Boudjema K, Raoul JL. Adjuvant intraarterial injection of 131I-labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case-control study with a 5-year minimal follow-up. J Nucl Med. 2008;49:362–6.
  Article PubMed Google Scholar
• Sun HC, Tang ZY, Wang L, et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol. 2006;132:458–65.
  Article CAS PubMed Google Scholar
• Hui D, Qiang L, Jian W, Ti Z, Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009;41:36–41.
  Article PubMed Google Scholar
• Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002;3:593–603.
  Article PubMed Google Scholar
• Samuel M, Chow PK, Chan SE, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev. 2009;CD001199.
• Xiao YS, Tang ZY, Fan J, et al. Interferon-alpha 2a up-regulated thymidine phosphorylase and enhanced antitumor effect of capecitabine on hepatocellular carcinoma in nude mice. J Cancer Res Clin Oncol. 2004;130:546–50.
  Article CAS PubMed Google Scholar
• Shim JH, Park JW, Nam BH, Lee WJ, Kim CM. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol. 2009;63:459–67.
  Article CAS PubMed Google Scholar
• von DS, Lersch C, Mayr M, Stock K, Schulte-Frohlinde E, Schmid RM, Eckel F. Capecitabine for treatment of advanced hepatocellular carcinoma. Hepatogastroenterology. 2007;54:2310–4.
  Google Scholar
• Patt YZ, Hassan MM, Aguayo A, et al. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma. Cancer. 2004;101:578–86.
  Article CAS PubMed Google Scholar
• Boige V, Raoul JL, Pignon JP, et al. Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial. Br J Cancer. 2007;97:862–7.
  CAS PubMed Google Scholar
• Poon RT. Differentiating early and late recurrences after resection of HCC in cirrhotic patients: implications on surveillance, prevention, and treatment strategies. Ann Surg Oncol. 2009;16:792–4.
  Article PubMed Google Scholar
• Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008;48:S20–37.
  Article CAS PubMed Google Scholar
• Portolani N, Coniglio A, Ghidoni S, Giovanelli M, Benetti A, Tiberio GA, Giulini SM. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243:229–35.
  Article PubMed Google Scholar
• Chau GY, Lui WY, Chi CW, Chau YP, Li AF, Kao HL, Wu CW. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection. Eur J Surg Oncol. 2008;34:333–8.
  PubMed Google Scholar
• Hu RH, Lee PH, Yu SC, Sheu JC, Lai MY. Serum hepatocyte growth factor before and after resection for hepatocellular carcinoma. Hepatogastroenterology. 1999;46:1842–7.
  CAS PubMed Google Scholar
• de Jong KP. Hepatocyte growth factor serum levels after partial hepatectomy. Transplantation. 2004;78:1089; author reply 1089–90.
  Article PubMed Google Scholar
• Horiguchi N, Takayama H, Toyoda M, et al. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine. Oncogene. 2002;21:1791–9.
  Article CAS PubMed Google Scholar
• Whitworth MK, Sheen A, Rosa DD, et al. Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. J Cancer Res Clin Oncol. 2006;132:41–4.
  Article CAS PubMed Google Scholar
• Park SH, Lee Y, Han SH, et al. Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer. 2006;6:3.
  Article PubMed Google Scholar